Nutriband (NASDAQ:NTRB) vs. Redhill Biopharma (NASDAQ:RDHL) Head-To-Head Contrast

Nutriband (NASDAQ:NTRB) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Valuation & Earnings

This table compares Nutriband and Redhill Biopharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04 million	20.74	-$8.23 million	($2.60)	-1.34
Redhill Biopharma	$290,000.00	18.08	-$430,000.00	$1,046.75	0.00

Redhill Biopharma has lower revenue, but higher earnings than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nutriband and Redhill Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutriband	-403.98%	-118.33%	-101.92%
Redhill Biopharma	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Nutriband and Redhill Biopharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1	1	0	0	1.50
Redhill Biopharma	1	0	0	0	1.00

Volatility & Risk

Nutriband has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, Redhill Biopharma has a beta of 5.05, suggesting that its share price is 405% more volatile than the S&P 500.

Insider and Institutional Ownership

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are owned by institutional investors. 52.2% of Nutriband shares are owned by insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Redhill Biopharma beats Nutriband on 7 of the 12 factors compared between the two stocks.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

About Redhill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.